Compile Data Set for Download or QSAR
Report error Found 130 for UniProtKB: Q9C005
TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552984(4-(difluoromethyl)-N-[4- fluoro-5-(2-morpholin-4- ...)
Affinity DataIC50: 36nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552953(US11319299, Example 8 | US11319299, Example Table...)
Affinity DataIC50: 43nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552953(US11319299, Example 8 | US11319299, Example Table...)
Affinity DataIC50: 43nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525707(US11174250, Example 125)
Affinity DataIC50: 49nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552952(N-[2-[(3S)-3,4- dimethylpiperazin-1-yl]- 4-fluoro-...)
Affinity DataIC50: 54nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552981(N-[5-(2-cyanopyrimidin- 5-yl)-4-fluoro-2-[(3S,5R)-...)
Affinity DataIC50: 75nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552987(N-[2-[(3R)-3- (dimethylamino)pyrrolidin- 1-yl]-4-f...)
Affinity DataIC50: 106nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552982(N-[4-fluoro-5-(6- morpholin-4-ylpyridin-3- yl)-2-[...)
Affinity DataIC50: 111nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552989(N-[5-[6- (cyclopropylmethoxy) pyridin-3-yl]-4-fluo...)
Affinity DataIC50: 174nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552978(N-[4-fluoro-5-(4- morpholin-4-ylphenyl)-2- [(3R,5S...)
Affinity DataIC50: 182nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525675(US11174250, Example 93)
Affinity DataIC50: 197nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525693(US11174250, Example 111)
Affinity DataIC50: 203nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552966(4-(difluoromethyl)-N-[4- fluoro-2-(4-methylpiperaz...)
Affinity DataIC50: 213nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525589(US11174250, Example 7)
Affinity DataIC50: 216nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552948(US11319299, Example 3 | N-[4-fluoro-2-(4- methylpi...)
Affinity DataIC50: 272nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552967(N-[2-[3-(dimethylamino) pyrrolidin-1-yl]-4-fluoro-...)
Affinity DataIC50: 272nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525628(US11174250, Example 46)
Affinity DataIC50: 290nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525706(US11174250, Example 124)
Affinity DataIC50: 293nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552986(N-[4-fluoro-5-pyridin-4- yl-2-[(3R,5S)-3,4,5- trim...)
Affinity DataIC50: 316nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525582(US11174250, Example Table4.4.2 | US11174250, Examp...)
Affinity DataIC50: 332nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552948(US11319299, Example 3 | N-[4-fluoro-2-(4- methylpi...)
Affinity DataIC50: 380nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552962(N-[5-(2-cyanopyrimidin- 5-yl)-4-fluoro-2-(4- methy...)
Affinity DataIC50: 467nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM553001((S)-N-(4-(3,4- dimethylpiperazin-1-yl)-6- fluoro-3...)
Affinity DataIC50: 478nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525627(US11174250, Example 45)
Affinity DataIC50: 514nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525609(US11174250, Example 27)
Affinity DataIC50: 529nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525664(US11174250, Example 82)
Affinity DataIC50: 549nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525578(US11174250, Example Table4.2.2 | US11174250, Examp...)
Affinity DataIC50: 592nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525578(US11174250, Example Table4.2.2 | US11174250, Examp...)
Affinity DataIC50: 592nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525692(US11174250, Example 110)
Affinity DataIC50: 607nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552985(N-[4-fluoro-5-pyridin-3- yl-2-[(3R,5S)-3,4,5- trim...)
Affinity DataIC50: 620nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525583(US11174250, Example 1)
Affinity DataIC50: 764nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552990(N-[5-[2- (dimethylamino)pyrimidin- 5-yl]-4-fluoro-...)
Affinity DataIC50: 774nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525608(US11174250, Example 26)
Affinity DataIC50: 779nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552995(N-(4-(3,4-dimethylpiperazin- 1-yl)-6-fluoro-3'- (m...)
Affinity DataIC50: 780nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552949(N-[4-fluoro-2-(4- methylpiperazin-1-yl)-5- (6-morp...)
Affinity DataIC50: 820nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM553006(US11319299, Comp. No. 56 | US11319299, Example 56 ...)
Affinity DataIC50: 864nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552951(N-[2-[(3R)-3,4- dimethylpiperazin-1-yl]- 4-fluoro-...)
Affinity DataIC50: 885nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525659(US11174250, Example 77)
Affinity DataIC50: 907nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525575(US11174250, Example Table4.1.2 | US11174250, Examp...)
Affinity DataIC50: 939nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525575(US11174250, Example Table4.1.2 | US11174250, Examp...)
Affinity DataIC50: 939nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525575(US11174250, Example Table4.1.2 | US11174250, Examp...)
Affinity DataIC50: 939nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525585(US11174250, Example 3)
Affinity DataIC50: 966nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552954(N-[4-fluoro-2-(4- methylpiperazin-1-yl)-5- (2-pyrr...)
Affinity DataIC50: 984nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552956(N-[5-[2-(cyclohexylamino) pyrimidin-5-yl]-4-fluoro...)
Affinity DataIC50: 993nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552980(N-[4-fluoro-2-(4- methylpiperazin-1-yl)-5- [6-(oxa...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM552983(N-[4-fluoro-5-(2- methylpyrimidin-5-yl)-2- [(3S,5R...)
Affinity DataIC50: 1.01E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525672(US11174250, Example 90)
Affinity DataIC50: 1.09E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525648(US11174250, Example 66)
Affinity DataIC50: 1.10E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525652(US11174250, Example 70)
Affinity DataIC50: 1.11E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525649(US11174250, Example 67)
Affinity DataIC50: 1.15E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 130 total ) | Next | Last >>
Jump to: